create a website

Cost Effectiveness of Pharmacological Maintenance Treatment for Chronic Obstructive Pulmonary Disease. (2012). Molken, Maureen Rutten-Van ; Goossens, Lucas .
In: PharmacoEconomics.
RePEc:spr:pharme:v:30:y:2012:i:4:p:271-302.

Full description at Econpapers || Download paper

Cited: 0

Citations received by this document

Cites: 90

References cited by this document

Cocites: 50

Documents which have cited the same bibliography

Coauthors: 0

Authors who have wrote about the same topic

Citations

Citations received by this document

    This document has not been cited yet.

References

References cited by this document

  1. Akazawa M, Hayflinger DC, Stanford RH, et al. Economic assessment of initial maintenance therapy for chronic obstructive pulmonary disease. Am J Manag Care 2008; 14: 438–48.
    Paper not yet in RePEc: Add citation now
  2. Akazawa M, Stearns SC, Biddle AK. Assessing treatment effects of inhaled corticosteroids on medical expenses and exacerbations among COPD patients: longitudinal analysis of managed care claims. Health Serv Res 2008; 43: 2164–82.
    Paper not yet in RePEc: Add citation now
  3. Andersson F, Borg S, Jansson SA, et al. The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respir Med 2002; 96: 700–8.
    Paper not yet in RePEc: Add citation now
  4. Ayres JG, Price MJ, Efthimiou J. Cost-effectiveness of fluticasone propionate in the treatment of chronic obstructive pulmonary disease: a double-blind randomized, placebocontrolled trial. Respir Med 2003; 97: 212–20.
    Paper not yet in RePEc: Add citation now
  5. Barton GR, Sach TH, Jenkinson C, et al. Do estimates of cost-utility based on the EQ-5D differ from those based on the mapping of utility scores? Health Qual Life Outcomes 2008; 6: 51.
    Paper not yet in RePEc: Add citation now
  6. Benayoun S, Ernst P, Suissa S. The impact of combined inhaled bronchodilator therapy in the treatment of COPD. Chest 2001; 119: 85–92.
    Paper not yet in RePEc: Add citation now
  7. Briggs AH, Glick HA, Lozano-Ortega G, et al. Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study. Eur Respir J 2010; 35: 532–9.
    Paper not yet in RePEc: Add citation now
  8. Briggs AH, Lozano-Ortega G, Spencer S, et al. Estimating the cost-effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data. Value Health 2006; 9: 227–35.
    Paper not yet in RePEc: Add citation now
  9. Buist AS, Vollmer WM, McBurnie MA. Worldwide burden of COPD in high- and low-income countries: part I. The burden of obstructive lung disease (BOLD) initiative. Int J Tuberc Lung Dis 2008; 12: 703–8.
    Paper not yet in RePEc: Add citation now
  10. Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. Eur Respir J Suppl 2003 Jun; 41: 46–53s.
    Paper not yet in RePEc: Add citation now
  11. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775–89.
    Paper not yet in RePEc: Add citation now
  12. Calverley PM, Rabe KF, Goehring UM, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009; 374: 685–94.
    Paper not yet in RePEc: Add citation now
  13. Calverley PM, Sanchez-Toril F, McIvor A, et al. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 176: 154–61.
    Paper not yet in RePEc: Add citation now
  14. Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008; 31: 416–69.
    Paper not yet in RePEc: Add citation now
  15. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932–46.
    Paper not yet in RePEc: Add citation now
  16. Chuck A, Jacobs P, Mayers I, et al. Cost-effectiveness of combination therapy for chronic obstructive pulmonary disease. Can Respir J 2008; 15: 437–43.
    Paper not yet in RePEc: Add citation now
  17. Collet JP, Ducruet T, Haider S, et al. Economic impact of using an immunostimulating agent to prevent severe acute exacerbations in patients with chronic obstructive pulmonary disease. Can Respir J 2001; 8: 27–33.
    Paper not yet in RePEc: Add citation now
  18. D’Souza AO, Smith MJ, Miller LA, et al. An appraisal of pharmacoeconomic evidence of maintenance therapy for COPD. Chest 2006; 129: 1693–708.
    Paper not yet in RePEc: Add citation now
  19. Dal Negro R, Eandi M, Pradelli L, et al. Cost-effectiveness and healthcare budget impact in Italy of inhaled corticosteroids and brochodilators for severe and very severe COPD patients. Int J Chronic Obstruct Pulmon Dis 2007; 2: 169–76.
    Paper not yet in RePEc: Add citation now
  20. Dal Negro R. Optimizing economic outcomes in the management of COPD. Int J Chron Obstruct Pulmon Dis 2008; 3: 1–10.
    Paper not yet in RePEc: Add citation now
  21. Dalal AA, Roberts MH, Petersen HV, et al. Comparative cost-effectiveness of a fluticasone-proprionate/salmeterol combination versus anticholinergics as maintenance therapy for chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2011; 6: 13–22.
    Paper not yet in RePEc: Add citation now
  22. Dalal AA, St Charles M, Petersen HV, et al. Cost-effectiveness of combination fluticasone propionate-salmeterol 250/50 mg versus salmeterol in severe COPD patients. Int J Chron Obstruct Pulmon Dis 2010; 5: 179–87.
    Paper not yet in RePEc: Add citation now

  23. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. 3rd ed. New York: Oxford University Press, 2005.

  24. Earnshaw SR, Wilson MR, Dalal AA, et al. Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPD. Respir Med 2009; 103: 12–21.
    Paper not yet in RePEc: Add citation now
  25. European Lung Foundation, European Respiratory Society. European Lung White Book. Lausanne: ERS, 2003.
    Paper not yet in RePEc: Add citation now
  26. Friedman M, Menjoge SS, Anton SF, et al. Healthcare costs with tiotropium plus usual care versus usual care alone following 1 year of treatment in patients with chronic obstructive pulmonary disorder (COPD). Pharmacoeconomics 2004; 22 (11): 741–9.
    Paper not yet in RePEc: Add citation now
  27. Friedman M, Serby CW, Menjoge SS, et al. Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. Chest 1999; 115: 635–41.
    Paper not yet in RePEc: Add citation now
  28. Gagnon YM, Levy AR, Spencer MD, et al. Economic evaluation of treating chronic obstructive pulmonary disease with inhaled corticosteroids and long-acting beta2-agonists in a health maintenance organization. Respir Med 2005; 99: 1534–45.
    Paper not yet in RePEc: Add citation now
  29. Gani R, Griffin J, Kelly S, et al. Economic analyses comparing tiotropium with ipratropium or salmeterol in UK patients with COPD. Prim Care Respir J 2010; 19: 68–74.
    Paper not yet in RePEc: Add citation now
  30. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2010 [online]. Available from URL: http://www.goldcopd.org/guidelines-global-strategy-for-diagnosi s-management.html [Accessed 2010 Apr 16].
    Paper not yet in RePEc: Add citation now
  31. Goossens LM, Nivens MC, Sachs P, et al. Is the EQ-5D responsive to recovery from a moderate COPD exacerbation? Respir Med 2011; 105 (8): 1195–202.
    Paper not yet in RePEc: Add citation now
  32. Grootendorst DC, Gauw SA, Verhoosel RM, et al. Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax 2007; 62: 1081–7.
    Paper not yet in RePEc: Add citation now
  33. Halpin DMG. Health economics of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006; 3: 227–33.
    Paper not yet in RePEc: Add citation now
  34. Harper R, Brazier JE, Waterhouse JC, et al. Comparison of outcome measures for patients with chronic obstructive pulmonary disease (COPD) in an outpatient setting. Thorax 1997; 52: 879–87.
    Paper not yet in RePEc: Add citation now
  35. Hogan TJ, Geddes R, Gonzalez ER. An economic assessment of inhaled formoterol dry powder versus ipratropium bromide pressurized metered dose inhaler in the treatment of chronic obstructive pulmonary disease. Clin Ther 2003; 25: 285–97.
    Paper not yet in RePEc: Add citation now
  36. Hoogendoorn M, Hoogenveen RT, Rutten-van Mölken MP, et al. Case fatality of COPD exacerbations: a meta-analysis and statistical modelling approach. Eur Respir J 2011; 37 (3): 508–15.
    Paper not yet in RePEc: Add citation now
  37. Jenkins C, Rodriguez-Roisin R. Quality of life, stage severity and COPD. Eur Respir J 2009; 33: 953–5.
    Paper not yet in RePEc: Add citation now
  38. Jones PW, Wilson K, Sondhi S. Cost-effectiveness of salmeterol in patients with chronic obstructive pulmonary disease: an economic evaluation. Respir Med 2003; 97: 20–6.
    Paper not yet in RePEc: Add citation now
  39. Jubran A, Gross N, Ramsdell J, et al. Comparative costeffectiveness analysis of theophylline and ipratropium bromide in chronic obstructive pulmonary disease. Chest 1993; 103: 678–84.
    Paper not yet in RePEc: Add citation now
  40. Löfdahl CG, Ericsson A, Svensson K, et al. Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone. Pharmacoeconomics 2005; 23 (4): 365–75.
    Paper not yet in RePEc: Add citation now
  41. Lee KH, Phua J, Lim TK. Evaluating the pharmacoeconomic effect of adding tiotropium bromide to the management of chronic obstructive pulmonary disease patients in Singapore. Respir Med 2006; 100: 2190–6.
    Paper not yet in RePEc: Add citation now
  42. Luijben AHP, Kommer GJ. Time-trends and future: part of the public health status and forecast report [report no.270061008; in Dutch]. Bilthoven: RIVM, 2010 [online]. Available from URL: http://www.vtv2010.nl/deelrapporten/tijd–toekomst/ [Accessed 2011 Nov 8].
    Paper not yet in RePEc: Add citation now
  43. Maniadakis N, Tzanakis N, Fragoulakis V, et al. Economic evaluation of tiotropium and salmeterol in the treatment of chronic obstructive pulmonary disease (COPD) in Greece. Curr Med Res Opin 2006; 22: 1599–607.
    Paper not yet in RePEc: Add citation now
  44. Mapel DW, Schum M, Lydick E, et al. A new method for examining the cost savings of reducing COPD exacerbations. Pharmacoeconomics 2010; 28 (9): 733–49.
    Paper not yet in RePEc: Add citation now
  45. Meguro M, Jones PW. Elicitation of utility weights for a COPD specific preference measure [abstract]. Am J Respir Crit Care Med 2006; 3: A488.
    Paper not yet in RePEc: Add citation now
  46. Miravitlles M, Ferrer M, Pont A, et al. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax 2004; 59: 387–95.
    Paper not yet in RePEc: Add citation now
  47. Mittmann N, Hernandez P, Mellström C, et al. Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish healthcare perspectives. Pharmacoeconomics 2011; 29 (5): 403–14.
    Paper not yet in RePEc: Add citation now
  48. Naik S, Kamal KM, Keys PA, et al. Evaluating the costeffectiveness of tiotropiumversus salmeterol in the treatment of chronic obstructive pulmonary disease. Clinico Economics Outcomes Res 2010; 2: 25–36.
    Paper not yet in RePEc: Add citation now
  49. Najafzadeh M, Marra CA, Sadatsafavi M, et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax 2008; 63: 962–7.
    Paper not yet in RePEc: Add citation now
  50. Neyt M, Devriese S, Thiry N, et al. Tiotropium’s costeffectiveness for the treatment of COPD: a cost-utility analysis under real-world conditions. BMC Pulm Med 2010; 10: 47.
    Paper not yet in RePEc: Add citation now
  51. O’Reilly JF, Williams AE, Rice L. Health status impairment and costs associated with COPD exacerbation managed in hospital. Int J Clin Pract 2007; 61: 1112–20.
    Paper not yet in RePEc: Add citation now
  52. Oba Y. Cost-effectiveness of long-acting bronchodilators for chronic obstructive pulmonary disease. Mayo Clin Proc 2007; 82: 575–82.
    Paper not yet in RePEc: Add citation now
  53. Oba Y. Cost-effectiveness of salmeterol, fluticasone, and combination therapy for COPD. Am J Manag Care 2009; 15: 226–32.
    Paper not yet in RePEc: Add citation now
  54. Onukwugha E, Mullins CD, DeLisle S. Using costeffectiveness analysis to sharpen formulary decision-making: the example of tiotropium at the Veterans Affairs health care system. Value Health 2008; 11: 980–8.
    Paper not yet in RePEc: Add citation now
  55. Oostenbrink JB, Rutten-van Mölken MPMH, Al MJ, et al. One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease. Eur Respir J 2004; 23: 241–9.
    Paper not yet in RePEc: Add citation now
  56. Oostenbrink JB, Rutten-van Mölken MPMH. Resource use and risk factors in high cost exacerbations of COPD. Respir Med 2004; 98: 883–91.
    Paper not yet in RePEc: Add citation now
  57. Oostenbrink JB, Rutten-van Molken MP, Monz BU, et al. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries. Value Health 2005; 8: 32–46.
    Paper not yet in RePEc: Add citation now
  58. Paterson C, Langan CE, McKaig GA, et al. Assessing patient outcomes in acute exacerbations of chronic bronchitis: the MeasureYour MedicalOutcome Profile (MYMOP),Medical Outcomes Study 6-item General Health Survey (MOS-6A) and EuroQol (EQ-5D). Qual Life Res 2000; 9: 521–7.
    Paper not yet in RePEc: Add citation now
  59. Petrillo J, van Nooten F, Jones P, et al. Utility estimation in chronic obstructive pulmonary disease: a preference for change? Pharmacoeconomics 2011; 29 (11): 917–32.
    Paper not yet in RePEc: Add citation now
  60. Postma DS, Calverley P. Inhaled corticosteroids in COPD: a case in favour. Eur Respir J 2009; 34: 10–2.
    Paper not yet in RePEc: Add citation now
  61. Price D, Gray A, Gale R, et al. Cost-utility analysis of indacaterol in Germany: a once-daily maintenance bronchodilator for patients with COPD. Respir Med 2011; 105: 1635–47.
    Paper not yet in RePEc: Add citation now
  62. Rabe KF, Bateman ED, O’Donnell D, et al. Roflumilast–an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2005; 366: 563–71.
    Paper not yet in RePEc: Add citation now
  63. Ringbaek T, Brondum E, Martinez G, et al. Euro QoL in assessment of the effect of pulmonary rehabilitation COPD patients. Respir Med 2008; 102: 1563–7.
    Paper not yet in RePEc: Add citation now
  64. Ruchlin HS, Dasbach EJ. An economic overview of chronic obstructive pulmonary disease. Pharmacoeconomics 2001; 19 (6): 623–42.
    Paper not yet in RePEc: Add citation now
  65. Rutten-van Mölken M, Lee TA. Economic modeling in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006; 3: 630–4.
    Paper not yet in RePEc: Add citation now

  66. Rutten-van Mölken MP, Oostenbrink JB, Miravitlles M, et al. Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain. Eur J Health Econ 2007; 8: 123–35.

  67. Rutten-van Mölken MP, Oostenbrink JB, Tashkin DP, et al. Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages? Chest 2006; 130: 1117–28.
    Paper not yet in RePEc: Add citation now
  68. Rutten-van Mölken MP, van Nooten FE, Lindemann M, et al. A 1-year prospective cost-effectiveness analysis of roflumilast for the treatment of patients with severe chronic obstructive pulmonary disease. Pharmacoeconomics 2007; 25 (8): 695–711.
    Paper not yet in RePEc: Add citation now
  69. Rutten-van Mölken MPMH, van Doorslaer EKA, Jansen MCC, et al. Costs and effects of inhaled corticosteroids and bronchodilators in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 151: 975–82.
    Paper not yet in RePEc: Add citation now
  70. Schramm W, Haake D, Brandt A. Economic value of tiotropium in the treatment of chronic obstructive pulmonary disease. Praxis (Bern 1994) 2005; 94: 1803–10.
    Paper not yet in RePEc: Add citation now
  71. Seemungal TA, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 1418–22.
    Paper not yet in RePEc: Add citation now
  72. Shiroiwa T, Sung Y, Fukuda T, et al. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost-effectiveness? Health Econ 2009; 19: 422–37.
    Paper not yet in RePEc: Add citation now
  73. Sin DD, Golmohammadi K, Jacobs P. Cost-effectiveness of inhaled corticosteroids for chronic obstructive pulmonary disease according to disease severity. Am J Med 2004; 116: 325–31.
    Paper not yet in RePEc: Add citation now

  74. Spencer M, Briggs AH, Grossman RF, et al. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics 2005; 23 (6): 619–37.

  75. Spencer S, Calverley PM, Burge PS, et al. Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J 2004; 23: 698–702.
    Paper not yet in RePEc: Add citation now
  76. Spencer S, Jones PW. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax 2003; 58: 589–93.
    Paper not yet in RePEc: Add citation now
  77. Ståhl E, Lindberg A, Jansson S-A, et al. Health-related quality of life is related to COPD disease severity. Health Qual Life Outcomes 2005; 3: 56.
    Paper not yet in RePEc: Add citation now
  78. Stahl E, Lindberg A, Jansson SA, et al. Health-related quality of life is related to COPD disease severity. Health Qual Life Outcomes 2005; 3: 56.
    Paper not yet in RePEc: Add citation now
  79. Starkie HJ, Briggs AH, Chambers MG. Pharmacoeconomics in COPD: lessons for the future. Int J Chron Obstruct Pulmon Dis 2008; 3: 71–88.
    Paper not yet in RePEc: Add citation now
  80. Stavem K. Reliability, validity and responsiveness of two multiattribute utility measures in patients with chronic obstructive pulmonary disease. Qual Life Res 1999; 8: 45–54.
    Paper not yet in RePEc: Add citation now
  81. Suissa S, Barnes PJ. Inhaled corticosteroids in COPD: the case against. Eur Respir J 2009; 34: 13–6.
    Paper not yet in RePEc: Add citation now
  82. Toy EL, Gallagher KF, Stanley EL, et al. The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: a review. COPD 2010; 7: 214–28.
    Paper not yet in RePEc: Add citation now
  83. US Department of Health and Human Services. National Institutes of Health, National Heart Lung and Blood Institute. Morbidity and mortality: 2007 chart book on cardiovascular, lung and blood diseases. 2007 Jun [online]. Available from URL: http://www.nhlbi.nih.gov/resources/docs/07-chtbk.pdf [Accessed 2011 Nov 8].
    Paper not yet in RePEc: Add citation now
  84. van den Boom G, Rutten-van Mölken MPMH, Molema J, et al. The cost effectiveness of early treatment with fluticasone propionate 250 microg twice a day in subjects with obstructive airway disease: results of the DIMCA program. Am J Respir Crit Care Med 2001; 164: 2057–66.
    Paper not yet in RePEc: Add citation now
  85. van der Palen J, Monninkhof E, van der Valk P, et al. Cost effectiveness of inhaled steroid withdrawal in outpatients with chronic obstructive pulmonary disease. Thorax 2006; 61: 29–33.
    Paper not yet in RePEc: Add citation now
  86. Van der Valk P, Monninkhof E, Van der Palen J, et al. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. Am J Respir Crit Care Med 2002; 166: 1358–63.
    Paper not yet in RePEc: Add citation now
  87. Verhage TL, Heijdra YF, Molema J, et al. Adequate patient characterization in COPD: reasons to go beyond GOLD classification. Open Respir Med J 2009; 3: 1–9.
    Paper not yet in RePEc: Add citation now
  88. Vogelmeier C, Hederer B, Glaab T, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011; 364: 1093–103.
    Paper not yet in RePEc: Add citation now
  89. World Health Organization. Chronic obstructive pulmonary disease [fact sheet no. 315]. Geneva: WHO, 2008 [online]. Available from URL: http://www.who.int/mediacentre/factsheets/fs315/en/ [Accessed 2010 Jun 1].
    Paper not yet in RePEc: Add citation now
  90. Wouters EF. Chronic obstructive pulmonary disease: 5. Systemic effects of COPD. Thorax 2002; 57: 1067–70.
    Paper not yet in RePEc: Add citation now

Cocites

Documents in RePEc which have cited the same bibliography

  1. Planning an integrated agriculture and health program and designing its evaluation: Experience from Western Kenya. (2016). Thiele, Graham ; Grant, Frederick ; Cole, Donald C ; Loechl, Cornelia ; Levin, Carol ; Girard, Aimee Webb ; Sindi, Kirimi ; Low, Jan.
    In: Evaluation and Program Planning.
    RePEc:eee:epplan:v:56:y:2016:i:c:p:11-22.

    Full description at Econpapers || Download paper

  2. Conceptualising quality of life outcomes for women participating in testing for sexually transmitted infections: A systematic review and meta-synthesis of qualitative research. (2015). Roberts, Tracy E ; Jackson, Louise J.
    In: Social Science & Medicine.
    RePEc:eee:socmed:v:143:y:2015:i:c:p:162-170.

    Full description at Econpapers || Download paper

  3. Basic versus supplementary health insurance: the role of cost effectiveness and prevalence. (2014). boone, jan.
    In: CEPR Discussion Papers.
    RePEc:cpr:ceprdp:10233.

    Full description at Econpapers || Download paper

  4. Basic versus supplementary health insurance: moral hazard and adverse selection. (2014). boone, jan.
    In: CEPR Discussion Papers.
    RePEc:cpr:ceprdp:10199.

    Full description at Econpapers || Download paper

  5. Revolution, evolution, or status quo? Guidelines for efficiency measurement in health care. (2012). Hollingsworth, Bruce.
    In: Journal of Productivity Analysis.
    RePEc:kap:jproda:v:37:y:2012:i:1:p:1-5.

    Full description at Econpapers || Download paper

  6. Comparing top-down and bottom-up costing approaches for economic evaluation within social welfare. (2011). Olsson, Tina .
    In: The European Journal of Health Economics.
    RePEc:spr:eujhec:v:12:y:2011:i:5:p:445-453.

    Full description at Econpapers || Download paper

  7. Cost study of the clinical management of prostate cancer in France: results on the basis of population-based data. (2011). Soulie, Michel ; Molinier, Laurent ; Daures, Jean-Pierre ; Bauvin, Eric ; Castelli, Christel ; Rebillard, Xavier ; Grosclaude, Pascale.
    In: The European Journal of Health Economics.
    RePEc:spr:eujhec:v:12:y:2011:i:4:p:363-371.

    Full description at Econpapers || Download paper

  8. Cost-Effectiveness Analysis of Education and Health Interventions in Developing Countries. (2011). McEwan, Patrick.
    In: SPD Working Papers.
    RePEc:idb:spdwps:1102.

    Full description at Econpapers || Download paper

  9. Informal Cost of Dementia Care – A Proxy-Good Valuation in Ireland. (2011). Trepel, Dominic.
    In: The Economic and Social Review.
    RePEc:eso:journl:v:42:y:2011:i:4:p:479-503.

    Full description at Econpapers || Download paper

  10. Modeling the long term health outcomes and cost-effectiveness of two interventions promoting fruit and vegetable intake among schoolchildren. (2011). Te Velde, Saskia J., ; Tak, Nannah I. ; Veerman, Lennert J. ; Klepp, Knut-Inge ; Bosmans, Judith E. ; Brug, Johannes.
    In: Economics & Human Biology.
    RePEc:eee:ehbiol:v:9:y:2011:i:1:p:14-22.

    Full description at Econpapers || Download paper

  11. The value of informal care–a further investigation of the feasibility of contingent valuation in informal caregivers. (2010). van Exel, Job ; Brouwer, Werner ; van den Berg, Bernard ; Koopmanschap, Marc ; de Meijer, Claudine.
    In: Health Economics.
    RePEc:wly:hlthec:v:19:y:2010:i:7:p:755-771.

    Full description at Econpapers || Download paper

  12. International survey on willingness‐to‐pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?. (2010). Shiroiwa, Takeru ; Fukuda, Takashi ; Bae, Sang-Cheol ; Tsutani, Kiichiro ; Lang, Hui-Chu ; Sung, Yoon-Kyoung.
    In: Health Economics.
    RePEc:wly:hlthec:v:19:y:2010:i:4:p:422-437.

    Full description at Econpapers || Download paper

  13. Systematic reviews of economic evaluations: utility or futility?. (2010). Anderson, Rob.
    In: Health Economics.
    RePEc:wly:hlthec:v:19:y:2010:i:3:p:350-364.

    Full description at Econpapers || Download paper

  14. Improving the measurement of QALYs in dementia: developing patient- and carer-reported health state classification systems using Rasch analysis. (2010). Rowen, Donna ; Knapp, M ; Brazier, J E ; Lamping, DL ; Mulhern, B ; Loftus, V ; Young, TA ; Smith, SC ; Banerjee, S ; Howard, R J.
    In: MPRA Paper.
    RePEc:pra:mprapa:29948.

    Full description at Econpapers || Download paper

  15. Health Technology Prioritisation: Which criteria for prioritising new technologies, and what are their relative weights?. (2010). Hansen, Paul ; Tal, Orna ; Golan, Ofra ; Kaplan, Giora.
    In: Working Papers.
    RePEc:otg:wpaper:1006.

    Full description at Econpapers || Download paper

  16. From a different angle: A novel approach to health valuation. (2010). Oppe, Mark ; Craig, Benjamin M..
    In: Social Science & Medicine.
    RePEc:eee:socmed:v:70:y:2010:i:2:p:169-174.

    Full description at Econpapers || Download paper

  17. Appropriate Perspectives for Health Care Decisions. (2010). Walker, Simon ; Sculpher, Mark ; Claxton, Karl ; Palmer, Steven.
    In: Working Papers.
    RePEc:chy:respap:54cherp.

    Full description at Econpapers || Download paper

  18. The valuation of prenatal life in economic evaluations of perinatal interventions. (2009). Gray, Alastair ; Petrou, Stavros ; Simon, Judit.
    In: Health Economics.
    RePEc:wly:hlthec:v:18:y:2009:i:4:p:487-494.

    Full description at Econpapers || Download paper

  19. Equality of what in health? Distinguishing between outcome egalitarianism and gain egalitarianism. (2009). Tsuchiya, Aki ; Dolan, Paul.
    In: Health Economics.
    RePEc:wly:hlthec:v:18:y:2009:i:2:p:147-159.

    Full description at Econpapers || Download paper

  20. How do physician assessments of patient preferences for colorectal cancer screening tests differ from actual preferences? A comparison in Canada and the United States using a stated‐choice survey. (2009). Kulin, Nathalie A. ; Phillips, Kathryn A. ; Judith M. E. Walsh, ; Marshall, John K. ; Van Bebber, Stephanie ; Zdemir, Semra ; JOHNSON, REED F..
    In: Health Economics.
    RePEc:wly:hlthec:v:18:y:2009:i:12:p:1420-1439.

    Full description at Econpapers || Download paper

  21. Long‐term care and hospital utilisation by older people: an analysis of substitution rates. (2009). Forder, Julien.
    In: Health Economics.
    RePEc:wly:hlthec:v:18:y:2009:i:11:p:1322-1338.

    Full description at Econpapers || Download paper

  22. Adjusting life for quality or disability: stylistic difference or substantial dispute?. (2009). Airoldi, Mara ; Morton, Alec.
    In: Health Economics.
    RePEc:wly:hlthec:v:18:y:2009:i:11:p:1237-1247.

    Full description at Econpapers || Download paper

  23. The economics of cochlear implant management in France: a multicentre analysis. (2009). Bongard, Vanina ; Molinier, Laurent ; Bocquet, Helene ; Fraysse, Bernard .
    In: The European Journal of Health Economics.
    RePEc:spr:eujhec:v:10:y:2009:i:3:p:347-355.

    Full description at Econpapers || Download paper

  24. The economic costs of Group B Streptococcus (GBS) disease: prospective cohort study of infants with GBS disease in England. (2009). Petrou, Stavros ; Heath, Paul ; Edamma, Oya ; Balfour, Gail ; Schroeder, Elizabeth-Ann.
    In: The European Journal of Health Economics.
    RePEc:spr:eujhec:v:10:y:2009:i:3:p:275-285.

    Full description at Econpapers || Download paper

  25. Health care costs, work productivity and activity impairment in non-malignant chronic pain patients. (2009). Kronborg, Christian ; Handberg, Gitte ; Axelsen, Flemming.
    In: The European Journal of Health Economics.
    RePEc:spr:eujhec:v:10:y:2009:i:1:p:5-13.

    Full description at Econpapers || Download paper

  26. Comparing methodologies for the cost estimation of hospital services. (2009). Redekop, W. ; Tan, S. ; Roijen, Hakkaart-van L. ; Rutten, F. ; Ineveld, B..
    In: The European Journal of Health Economics.
    RePEc:spr:eujhec:v:10:y:2009:i:1:p:39-45.

    Full description at Econpapers || Download paper

  27. Using rank and discrete choice data to estimate health state utility values on the QALY scale. (2009). Tsuchiya, Aki ; Rowen, Donna ; Brazier, John ; Yang, Y.
    In: MPRA Paper.
    RePEc:pra:mprapa:29891.

    Full description at Econpapers || Download paper

  28. The simultaneous valuation of states from multiple instruments using ranking and VAS data: methods and preliminary results. (2009). Tsuchiya, Aki ; Rowen, Donna ; Hernandez Alava, Monica ; Brazier, John ; Ibbotson, R.
    In: MPRA Paper.
    RePEc:pra:mprapa:29841.

    Full description at Econpapers || Download paper

  29. Activity based payment in hospitals: Principles and issues drawn from the economic literature and country experiences. (2009). RENAUD, Thomas ; Or, Zeynep.
    In: Working Papers.
    RePEc:irh:wpaper:dt23.

    Full description at Econpapers || Download paper

  30. Framework for the cost benefit analysis of the NSW Department of Community Services Brighter Futures Program. CHERE Working Paper 2009/4.. (2009). Tannous, Wadad ; Haas, Marion ; Gallego, Gisselle ; van Gool, Kees ; Katz, Ilan.
    In: Working Papers.
    RePEc:her:chewps:2009/4.

    Full description at Econpapers || Download paper

  31. A note on the nature of utility in time and health and implications for cost utility analysis. (2009). Devlin, Nancy ; Buckingham, Ken J..
    In: Social Science & Medicine.
    RePEc:eee:socmed:v:68:y:2009:i:2:p:362-367.

    Full description at Econpapers || Download paper

  32. Confidence interval estimation for lognormal data with application to health economics. (2009). Taleban, Julia ; Zou, Guang Yong ; Huo, Cindy Y..
    In: Computational Statistics & Data Analysis.
    RePEc:eee:csdana:v:53:y:2009:i:11:p:3755-3764.

    Full description at Econpapers || Download paper

  33. A comparison of the performance of the EQ‐5D and SF‐6D for individuals aged ≥ 45 years. (2008). Muir, Kenneth R. ; Barton, Garry R. ; Whynes, David K. ; Jenkinson, Claire ; Avery, Anthony J. ; Sach, Tracey H. ; Doherty, Michael.
    In: Health Economics.
    RePEc:wly:hlthec:v:17:y:2008:i:7:p:815-832.

    Full description at Econpapers || Download paper

  34. Contingent valuation in health care: does it matter how the ‘good’ is described?. (2008). Smith, Richard D..
    In: Health Economics.
    RePEc:wly:hlthec:v:17:y:2008:i:5:p:607-617.

    Full description at Econpapers || Download paper

  35. HPV triage testing or repeat Pap smear for the management of atypical squamous cells (ASCUS) on Pap smear: is there evidence of process utility?. (2008). Irwig, Les ; McCaffery, Kirsten ; Howard, Kirsten ; Salkeld, Glenn.
    In: Health Economics.
    RePEc:wly:hlthec:v:17:y:2008:i:5:p:593-605.

    Full description at Econpapers || Download paper

  36. On future non‐medical costs in economic evaluations. (2008). Stlhammar, Nils-Olov ; Karlsson, Goran S. ; Liljas, Bengt.
    In: Health Economics.
    RePEc:wly:hlthec:v:17:y:2008:i:5:p:579-591.

    Full description at Econpapers || Download paper

  37. Incorporating feelings related to the uncertainty about future health in utility measurement. (2008). Gandjour, Afschin.
    In: Health Economics.
    RePEc:wly:hlthec:v:17:y:2008:i:10:p:1207-1213.

    Full description at Econpapers || Download paper

  38. Economic evaluation of innovative technologies in health care should include a short-run perspective. (2008). Adang, Eddy.
    In: The European Journal of Health Economics.
    RePEc:spr:eujhec:v:9:y:2008:i:4:p:381-384.

    Full description at Econpapers || Download paper

  39. Methodological issues in undertaking independent cost-effectiveness analysis for NICE: the case of therapies for ADHD. (2008). Griffin, Susan ; Drummond, Mike ; Weatherly, Helen ; Richardson, Gerry.
    In: The European Journal of Health Economics.
    RePEc:spr:eujhec:v:9:y:2008:i:2:p:137-145.

    Full description at Econpapers || Download paper

  40. Including quality attributes in a model of health care efficiency: A net benefit approach. (2008). Coelli, Timothy ; Eckermann, Simon.
    In: CEPA Working Papers Series.
    RePEc:qld:uqcepa:31.

    Full description at Econpapers || Download paper

  41. Early discharge and home intervention reduces unit costs after total hip replacement: results of a cost analysis in a randomized study. (2008). Sigurðsson, Eyjólfur ; Matthíasson, Þórólfur ; Siggeirsdottir, Kristin ; Jonsson, Halldor ; Gudnason, Vilmundur ; Matthiasson, Thorolfur.
    In: International Journal of Health Economics and Management.
    RePEc:kap:ijhcfe:v:8:y:2008:i:3:p:181-192.

    Full description at Econpapers || Download paper

  42. Analyzing the determinants of willingness-to-pay values for testing the validity of the contingent valuation method. Application to home care compared to hospital care. (2008). Havet, Nathalie ; Remonnay, Raphael ; Carrere, Marie-Odile ; Morelle, Magali.
    In: Post-Print.
    RePEc:hal:journl:halshs-00303725.

    Full description at Econpapers || Download paper

  43. Analyzing the determinants of willingness-to-pay values for testing the validity of the contingent valuation method. Application to home care compared to hospital care. (2008). Havet, Nathalie ; Remonnay, Raphael ; Carrere, Marie-Odile ; Morelle, Magali.
    In: Working Papers.
    RePEc:gat:wpaper:0820.

    Full description at Econpapers || Download paper

  44. ‘Is there a case for using visual analogue scale valuations in CUA? Yes there is a case, but what does it add to ordinal data?’ a rejoinder. (2007). Parkin, David ; Devlin, Nancy.
    In: Health Economics.
    RePEc:wly:hlthec:v:16:y:2007:i:6:p:649-651.

    Full description at Econpapers || Download paper

  45. ‘Is there a case for using visual analogue scale valuations in CUA’ by Parkin and Devlin a response: ‘yes there is a case, but what does it add to ordinal data?’. (2007). McCabe, Christopher ; Brazier, John.
    In: Health Economics.
    RePEc:wly:hlthec:v:16:y:2007:i:6:p:645-647.

    Full description at Econpapers || Download paper

  46. A comparison of United States and United Kingdom EQ-5D health states valuations using a nonparametric Bayesian method. (2007). Brazier, John ; Kharroubi, S A ; O'Hagan, A.
    In: MPRA Paper.
    RePEc:pra:mprapa:29806.

    Full description at Econpapers || Download paper

  47. A theoretical framework for TTO valuations of health. (2006). Devlin, Nancy ; Buckingham, Ken.
    In: Health Economics.
    RePEc:wly:hlthec:v:15:y:2006:i:10:p:1149-1154.

    Full description at Econpapers || Download paper

  48. The Dutch tariff: results and arguments for an effective design for national EQ‐5D valuation studies. (2006). P. F. M. Stalmeier, ; P. F. M. Krabbe, ; Lamers, L. M. ; McDonnell, J. ; J. J. V. Busschbach, .
    In: Health Economics.
    RePEc:wly:hlthec:v:15:y:2006:i:10:p:1121-1132.

    Full description at Econpapers || Download paper

  49. Evidence-Based Illicit Drug Policy: The Potential Contribution of Economic Evaluation Techniques. (2006). .
    In: De Economist.
    RePEc:kap:decono:v:154:y:2006:i:4:p:563-580.

    Full description at Econpapers || Download paper

  50. Generalisable regression methods for costeffectiveness using copulas. (2005). Quinn, Casey.
    In: Health, Econometrics and Data Group (HEDG) Working Papers.
    RePEc:yor:hectdg:05/13.

    Full description at Econpapers || Download paper

Coauthors

Authors registered in RePEc who have wrote about the same topic

Report date: 2025-09-21 09:00:49 || Missing content? Let us know

CitEc is a RePEc service, providing citation data for Economics since 2001. Last updated August, 3 2024. Contact: Jose Manuel Barrueco.